PROCEPT BioRobotics Corporation $PRCT Shares Acquired by FirstWave Capital Management LLC

FirstWave Capital Management LLC boosted its holdings in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 79.7% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 144,408 shares of the company’s stock after purchasing an additional 64,069 shares during the period. PROCEPT BioRobotics comprises 1.4% of FirstWave Capital Management LLC’s portfolio, making the stock its 21st largest position. FirstWave Capital Management LLC owned 0.25% of PROCEPT BioRobotics worth $3,261,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Versant Capital Management Inc raised its position in shares of PROCEPT BioRobotics by 994.5% in the 2nd quarter. Versant Capital Management Inc now owns 1,193 shares of the company’s stock valued at $27,000 after purchasing an additional 1,084 shares in the last quarter. Nykredit A S acquired a new stake in shares of PROCEPT BioRobotics during the second quarter worth approximately $27,000. Caitong International Asset Management Co. Ltd increased its stake in shares of PROCEPT BioRobotics by 436.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock worth $29,000 after buying an additional 746 shares during the last quarter. Center for Financial Planning Inc. acquired a new stake in PROCEPT BioRobotics in the fourth quarter valued at $40,000. Finally, Cache Advisors LLC acquired a new stake in PROCEPT BioRobotics in the first quarter valued at $42,000. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PRCT has been the subject of several recent analyst reports. Leerink Partners lowered shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $31.00 to $29.00 in a report on Thursday, June 11th. TD Cowen reduced their price target on shares of PROCEPT BioRobotics from $34.00 to $28.00 and set a “buy” rating on the stock in a research report on Wednesday, August 5th. Piper Sandler lowered their price objective on PROCEPT BioRobotics from $35.00 to $25.00 and set an “overweight” rating for the company in a report on Wednesday, August 5th. UBS Group lowered PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 price objective for the company. in a report on Tuesday, July 28th. Finally, Truist Financial set a $21.00 target price on PROCEPT BioRobotics in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, PROCEPT BioRobotics presently has a consensus rating of “Hold” and a consensus target price of $25.09.

PROCEPT BioRobotics News Roundup

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: The stock’s increase suggests investors may be treating the latest announcements as repetitive legal notices rather than a new deterioration in the company’s business. The reports did not announce a judgment, settlement, regulatory penalty, or additional financial charge.
• Neutral Sentiment: Multiple firms—including Kaplan Fox class action deadline Kaplan Fox, Hagens Berman investor deadline Hagens Berman, and Rosen Law investor deadline Rosen Law—reminded investors that September 22, 2026 is the deadline to seek lead-plaintiff status. The proposed class covers purchases made from February 28, 2024, through February 25, 2026.
• Negative Sentiment: The lawsuit alleges that PROCEPT made misleading statements or failed to disclose repeated weakness in unit handpiece sales and excess customer inventory, allegedly caused in part by late-quarter bulk discounts. Law firms say these issues contributed to a substantial stock decline, including an approximately 18% drop cited in the filings. The allegations remain unproven, but continued litigation could increase costs, management distraction, and investor uncertainty. Hagens Berman securities fraud lawsuit

Insider Transactions at PROCEPT BioRobotics

In related news, CEO Larry Wood acquired 23,900 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average cost of $20.85 per share, for a total transaction of $498,315.00. Following the purchase, the chief executive officer directly owned 23,900 shares in the company, valued at $498,315. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. In the last ninety days, insiders sold 1,000 shares of company stock worth $28,480. Insiders own 4.00% of the company’s stock.

PROCEPT BioRobotics Trading Up 6.5%

PROCEPT BioRobotics stock opened at $22.76 on Friday. PROCEPT BioRobotics Corporation has a 1 year low of $16.67 and a 1 year high of $41.51. The firm’s 50-day moving average is $20.35 and its 200-day moving average is $23.69. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.35 and a current ratio of 6.55. The company has a market cap of $1.30 billion, a P/E ratio of -11.73 and a beta of 0.91.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.The business had revenue of $94.50 million for the quarter, compared to analyst estimates of $92.77 million. During the same quarter last year, the company earned ($0.35) EPS. PROCEPT BioRobotics’s revenue was up 19.3% compared to the same quarter last year. On average, equities analysts expect that PROCEPT BioRobotics Corporation will post -1.67 earnings per share for the current year.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.